Drug Profile
Zelpultide alfa - Airway Therapeutics
Alternative Names: AT-100; rhSP-DLatest Information Update: 12 Jun 2023
Price :
$50
*
At a glance
- Originator Airway Therapeutics
- Class Anti-infectives; Anti-inflammatories; Antivirals; Recombinant proteins
- Mechanism of Action Cell membrane permeability enhancers; Protein replacements; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Bronchopulmonary dysplasia; COVID 2019 infections
- Preclinical Influenza virus infections; Respiratory syncytial virus infections
- Research Inflammation; Respiration disorders
Most Recent Events
- 05 Jun 2023 Airway Therapeutics completes enrolment in its phase Ib trial for Bronchopulmonary dysplasia in USA and Spain
- 05 Jun 2023 Airway Therapeutics plans a phase III trial for Bronchopulmonary dysplasia in North America and Europe by the end of 2023
- 27 Feb 2023 Early research in Inflammation in USA (unspecified route) (Airway Therapeutics pipeline, February 2023)